Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
Current NICE guidelines for type 2 diabetes (T2D) recommend identifying the most appropriate glucose-lowering therapy for a given individual. This decision depends not only on the initial glycaemic response, but also the durability of its glucose lowering effect over time. We investigated the latter...
Main Authors: | Agbaje, O, Coleman, R, Hattersley, A, Pearson, E, Holman, R, MASTERMIND Consortium |
---|---|
Format: | Conference item |
Published: |
Springer
2017
|
Similar Items
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
by: Kahn, SE, et al.
Published: (2006) -
FASTING BLOOD-GLUCOSE CONCENTRATIONS AND TREATMENT OF MATURITY-ONSET DIABETES
by: Howedavies, S, et al.
Published: (1980) -
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
by: McGovern, A, et al.
Published: (2019) -
Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.
by: Holman, R, et al.
Published: (1979) -
The basal plasma glucose: a simple relevant index of maturity-onset diabetes.
by: Holman, R, et al.
Published: (1981)